During the “Rising Stars” session on Saturday, Sept. 26th at the International Myeloma Workshop (IMW) in Rome—co-chaired by IMW organizer Dr. Antonio Palumbo and myself—Dr. Bruno Paiva from the University of Navarra in Pamplona, Spain was awarded the newly established Bart Barlogie Young Investigator Award. This award honors an investigator under 40 years old at the time of the IMW who has made major scientific contributions in terms of publications, funding received and prior awards or recognition. Bruno has been amazingly prolific at a young age: he is only 31, yet beat out investigators all the way up to age 40!

Bruno's primary research area is the assessment of minimal residual disease (MRD). Among other things, he is the lead investigator for the studies of next-generation flow (NGF) and sequencing as part of the IMF’s Black Swan Research Initiative®. Thus this award acknowledges Bruno individually and the importance of the MRD approach to searching for a cure for myeloma.

Bruno has been a prominent presenter at the annual meeting of the American Society of Hematology (ASH) in recent years, with key presentations on multiple aspects of MRD. One study, for example, focused on the nature of residual subclones after primary induction therapy. Another compared results with NGF versus next-generation sequencing (NGS) in determining the best response at the MRD-negative level.

Bruno gave a very gracious and humble acceptance speech, which you can listen to here, pointing out the contributions of the other team members and, of course, his primary mentor, Prof. Jesús San Miguel. Dr. San Miguel brought Bruno with him as his lead investigator when he moved from the University of Salamanca in Spain to Pamplona. They are certainly an indomitable duo!

We congratulate Bruno and wish him the greatest success in the coming years, which will undoubtedly be extraordinary in their contributions to the myeloma community.   Bruno, a truly stellar individual, so well represents the “Rising Stars” who were honored as the IMW Congress in Rome came to a close. 

The “Rising Stars” session also acknowledged four other excellent young researchers, who presented summaries of their research. Prof. Palumbo emphasized the importance of this part of the program in bringing fresh ideas to the table, and contributing to a better understanding of myeloma and approaches to treatment. I am sure we can expect more of this in the future!

Dr. Durie sincerely appreciates and reads all comments left here. However, he cannot answer specific medical questions and encourages readers to contact the trained IMF InfoLine staff instead. Specific medical questions posted here will be forwarded to the IMF InfoLine. Questions sent to the InfoLine are answered with input from Dr. Durie and/or other scientific advisors and IMWG members as appropriate, but will not be posted here. To contact the IMF InfoLine, call 800-452-CURE, toll-free in the US and Canada, or send an email to infoline@myeloma.org. InfoLine hours are 9 am to 4 pm PT. Thank you.



Previous Post
#AskDrDurie: Should I Be On Maintenance Therapy?
Next Post
Miscellany: A recap of IMW 2015, a drug cost report from Tufts, and vacation reading that matters

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.